Perhaps most important;"80% (4/5) of evaluable patients showed...

Perhaps most important;
"80% (4/5) of evaluable patients showed further reductions in spleen volume from Week 24 to Week 38 which is a novel finding that differentiates SNT-5505 from other treatments on market and in development."

"82% (9/11) of evaluable patients3 experienced stable or reduced spleen volume with no dosage adjustments in RUX."

"30% (3/10) of evaluable patients achieved an SVR25 and 20% (2/10) achieved an SVR35 with indications that patients were improving further at later timepoints".
(improving further is important)

"Notably, spleen reductions over the period of the interim data were achieved in patients despite significant duration (>2 years) prior RUX exposure with many on low daily doses (≤20 mg/day)."